Medicon Valley Academy's newly published Q1 2006 figures show investments in medical biotechnology companies in Medicon Valley totalled DKK 109 m (USD 18.5 m), more than a twofold increase compared to Q4 2005 when investments totalled DKK 45 m (USD 7.7 m). Since the end of the first quarter, even more cash has been raised following IPOs of Curalogic on the Copenhagen Stock Exchange and Osteologix on the OTC bourse in the US.
Jesper Zeuthen, head of BankInvest's biotech investments comments: "Denmark is doing very well. It is highly unusual that such a small country as Denmark has so many mature biotech companies, and that international investors are practically queuing up to join in."
Peter Benson, director of another of Denmark's large biotech investors, Life Science Ventures, has an optimistic outlook for Danish biotech industry: "I think we are only seeing the beginning for Danish biotech industry this spring. Over the next couple of years, we will see more companies become stock exchange listed, and perhaps foreign buy-ups." Peter Benson also says that in recent years, Danish biotech companies have had many foreign investors, and that the number of visits from investors is also increasing. The news was reported by professional journal Ingeniøren (The Engineer).
Medicon Valley is one of Europe's strongest life science clusters. It spans the Greater Copenhagen area in Denmark and the Skåne region of southern Sweden. Medicon Valley comprises life science companies, universities, hospitals, science parks, innovation environments, investors and business services.
Link > Medicon Valley Academy